Search Result

Results for "

cannabinoid receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cannabinoid Receptor (144) 5-HT Receptor (1) Androgen Receptor (1) Apoptosis (1) Autophagy (11) Bacterial (5) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) Cytochrome P450 (2) DAGL (2) Endogenous Metabolite (26) FAAH (3) FABP (1) Fatty Acid Synthase (FASN) (1) Fungal (2) GPR55 (5) Isotope-Labeled Compounds (8) NF-κB (2) NO Synthase (2) P-glycoprotein (1) PDK-1 (1) PPAR (2) Tau Protein (2) TRP Channel (15)
By Research Areas:	Cancer (16) Cardiovascular Disease (3) Endocrinology (1) Infection (7) Inflammation/Immunology (24) Metabolic Disease (31) Neurological Disease (97)
Click Chemistry:	Azide (1)

158

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Cannabinoid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117139

NESS 0327	Cannabinoid Receptor	Neurological Disease
NESS 0327 is a *cannabinoid* antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor .

HY-N2911

Auriculasin	Cannabinoid Receptor	Neurological Disease
Auriculasin is a nature product isolated from *Limonium leptophyllum. Auriculasin has activity toward cannabinoid* receptor type 1 (CB1) with an IC₅₀ value of 8.92 µM .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid CB2 receptor full agonist .

HY-152270

Pirnabine	Cannabinoid Receptor	Neurological Disease
Pirnabine is a **cannabinoid receptor** ligand. Pirnabine can be used for the research of glaucoma .

HY-103336

Tocrifluor 1117 T1117	GPR55 Cannabinoid Receptor	Cardiovascular Disease
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) .

HY-133533

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity **cannabinoid CB₁ receptor antagonist with a K_i** of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice .

HY-149644

CB2R agonist 3	Cannabinoid Receptor	Inflammation/Immunology
CB2R agonist 3 is an agonist of **cannabinoid receptor 2 (CB2R), with EC₅₀** of 0.37μM that plays an important role in immune system .

HY-151105

CBR Agonist-1	Cannabinoid Receptor	Neurological Disease
CBR Agonist-1 (27a-cis) is a cannabinoid receptor (CBR) agonist with the K_i values of 0.18 μM for CB₁R and 1.22 μM for CB₂R. CBR Agonist-1 (27a-cis) can be used in the study of endogenous cannabinoid system-related diseases .

HY-125972

zr17-2	Cannabinoid Receptor	Neurological Disease
zr17-2 is a potent **cannabinoid CB1 receptor** modulator. zr17-2 reduces oxidative stress-induced retinal cell death .

HY-122153

VSN-16	Cannabinoid Receptor	Cardiovascular Disease Inflammation/Immunology
VSN-16 is a **cannabinoid receptor** agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .

HY-N6097

Amauromine	Cannabinoid Receptor	Neurological Disease
Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with K_i and K_b values of 178 nM and 66.6 nM, respectively .

HY-156831

AEF0117	Cannabinoid Receptor	Neurological Disease
AEF0117 is a signaling-specific inhibitor of the **cannabinoid receptor** 1 (CB1-SSi). AEF0117 plays an important role in Cannabis use disorder (CUD) .

HY-149993

hBChE-IN-2	Cholinesterase (ChE) Cannabinoid Receptor	Neurological Disease
hBChE-IN-2 (compound 15d) is a butyrylcholinesterase (BChE) inhibitor (IC₅₀ of 0.62 μM) and a cannabinoid receptor 2 (CB2R) agonist. hBChE-IN-2 has neuroprotection activities .

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Metabolic Disease Cancer
Voacamine, an indole alkaloid, exhibits potent **cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp**) action in multidrug-resistant tumor cells .

HY-110050

GP1a	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .

HY-113689

GAT211	Cannabinoid Receptor	Neurological Disease
GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC₅₀ values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research .

HY-145604

Vicasinabin RG7774	Cannabinoid Receptor	Neurological Disease
Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1) .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a peripherally active, **cannabinoid receptor antagonist with limited brain penetration. AM6545 binds to CB1 and CB2** receptors with K_is of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist. AM6545 can be used for the research of obesity and its complications .

HY-144827

AM8936	Cannabinoid Receptor	Neurological Disease Metabolic Disease
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC₅₀s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with K_i of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc .

HY-135882

OMDM-6	TRP Channel Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
OMDM-6 is a hybrid agonist of *vanilloid receptor* type 1 (VR1, TRPV1) (EC₅₀*=75 nM) and cannabinoid* receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	TRP Channel Endogenous Metabolite	Neurological Disease
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent *vanilloid receptor* type 1 (VR1, TRPV1) agonist, with an EC₅₀** of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-W005629

Leelamine	Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

HY-100197

Synaptamide 1 Publications Verification N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide	Cannabinoid Receptor	Neurological Disease
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-14791A

(±)-Ibipinabant 1 Publications Verification (±)-SLV319; (±)-BMS-646256	Cannabinoid Receptor	Metabolic Disease
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

HY-134110

N-Methylarachidonamide	Endogenous Metabolite	Metabolic Disease
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-134055

Arachidonoyl-N,N-dimethyl amide Arachidonic acid-N,N-dimethyl amide	Cannabinoid Receptor	Metabolic Disease
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.

HY-10013A

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the *Cannabinoid-1* (CB1) *receptor* extracted from patent WO 2004048317 A1 .

HY-123594

R-2 Methanandamide	Cannabinoid Receptor	Neurological Disease
R-2 Methanandamide (Compound 2) is a *cannabinoid* Anandamide (HY-10863) analog with a K_i of 119 nM for the cannabinoid receptor (K_i is determined using rat brain membranes with PMSF) .

HY-103330

TC-C 14G	Cannabinoid Receptor	Neurological Disease
TC-C 14G (Compd 14g) is a Cannabinoid-1 Receptor (CB1R) inverse agonist, with a K_i of 4 nM and EC₅₀ of 11 nM for HCB1R, respectively .

HY-121545

CB-52	Cannabinoid Receptor	Inflammation/Immunology
CB-52 is the ligand and neutral antagonist of CB2 cannabinoid receptor .

HY-121637

IDFP iso-Prdodecylfluorophosphonate	Cannabinoid Receptor	Neurological Disease
IDFP (iso-Prdodecylfluorophosphonate) is a chemical affinity probe for the cannabinoid CB1 receptor .

HY-120953

GAT228	Cannabinoid Receptor	Inflammation/Immunology
GAT228, the enantiomer of GAT211, is an allosteric cannabinoid receptor 1 (CB1) ligand .

HY-130357

15(S)-HETE Ethanolamide	Cannabinoid Receptor	Others
15(S)-HETE Ethanolamide is a cannabinoid analog the CB1 receptor (K_i of 600 nM) .

HY-110016

Docosatetraenylethanolamide DEA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a K_i value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .

HY-14160

CB2 receptor agonist 7	Cannabinoid Receptor	Neurological Disease Cancer
CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability .

HY-105238

JHU-75528	Cannabinoid Receptor	Neurological Disease
JHU-75528 is a novel ligand of the cannabinoid receptor (CB1). JHU-75528 can be used in the research of imaging CB1 receptor .

HY-120653

CB1 antagonist 5	Cannabinoid Receptor	Neurological Disease
CB1 antagonist 5 (Compound 25) is an antagonist for CB1 cannabinoid receptor, with a K_i of 243 nM and an EC₅₀ of 195 nM .

HY-153800

Monlunabant (S)-MRI-1891; INV-202	Cannabinoid Receptor	Neurological Disease
Monlunabant ((S)-MRI-1891) is a solid dispersions compound, as well as a cannabinoid CB1 receptor inhibitor .

HY-159115

ART26.12	FABP Cannabinoid Receptor	Metabolic Disease
ART26.12 is an orally active FABP5 inhibitor with anti-cannabinoid properties. ART26.12 effectively prevents and alleviates Oxaliplatin (HY-17371)-induced pain through lipid modulation and **cannabinoid receptor** activation .

HY-12761

A-836339	Cannabinoid Receptor	Neurological Disease
A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-100328

CB2R-IN-1	Cannabinoid Receptor	Neurological Disease
CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K_i of 0.9 nM.

HY-134615

Mead ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Mead ethanolamide is an endogenous **cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2**, respectively .

HY-10871

Otenabant 2 Publications Verification CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-10871A

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-146134

PGN36	Cannabinoid Receptor	Inflammation/Immunology
PGN36 (Compound 18) is a selective cannabinoid CB₂ receptor (CB₂R) antagonist with a K_i of 0.09 µM .

HY-N0919

Yangonin 1 Publications Verification	Cannabinoid Receptor NF-κB Autophagy	Inflammation/Immunology
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-150067

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀ value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity .

Cat. No.	Product Name

HY-L006

GPCR/G Protein Compound Library

2,528 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provides a unique collection of 2,528 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

Cat. No.	Product Name	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cell Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Drug Delivery

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Target	Research Area

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-152270

Pirnabine	Cannabinoid Receptor	Neurological Disease
Pirnabine is a **cannabinoid receptor** ligand. Pirnabine can be used for the research of glaucoma .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6932

Voacamine	Alkaloids Structural Classification other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Indole Alkaloids	Cannabinoid Receptor P-glycoprotein
Voacamine, an indole alkaloid, exhibits potent **cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp**) action in multidrug-resistant tumor cells .

HY-N0919

Yangonin 1 Publications Verification	Structural Classification other families Classification of Application Fields Source classification Other Phenylpropanoids Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	Cannabinoid Receptor NF-κB Autophagy
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-116637

Tetrahydromagnolol Magnolignan	Structural Classification Classification of Application Fields Source classification Magnoliaceae Phenols Polyphenols Magnolia Liliflora Desr. Plants Inflammation/Immunology Disease Research Fields	Cannabinoid Receptor GPR55
Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective **cannabinoid CB2 receptor agonist with an EC₅₀ of 170 nM and a K_i** of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist .

HY-N6097

Amauromine	Structural Classification Alkaloids Microorganisms Source classification Indole Alkaloids	Cannabinoid Receptor
Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with K_i and K_b values of 178 nM and 66.6 nM, respectively .

HY-135882

OMDM-6	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	TRP Channel Cannabinoid Receptor Endogenous Metabolite
OMDM-6 is a hybrid agonist of *vanilloid receptor* type 1 (VR1, TRPV1) (EC₅₀*=75 nM) and cannabinoid* receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent *vanilloid receptor* type 1 (VR1, TRPV1) agonist, with an EC₅₀** of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-110016

Docosatetraenylethanolamide DEA	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Cannabinoid Receptor
Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a K_i value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-134615

Mead ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Mead ethanolamide is an endogenous **cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2**, respectively .

HY-113516

20-HETE Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a K_i of 985 nM .

HY-116418

Virodhamine	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Cannabinoid Receptor
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-N0919R

Yangonin (Standard)	Structural Classification other families Source classification Other Phenylpropanoids Phenylpropanoids Plants	Cannabinoid Receptor NF-κB Autophagy
Yangonin (Standard) is the analytical standard of Yangonin. This product is intended for research and analytical applications. Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC50 and a Ki of 1.79 μM and 0.72 μM, respectively.

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-110028

Leelamine hydrochloride	Structural Classification other families Classification of Application Fields Pinaceae Terpenoids Source classification Diterpenoids Plants Disease Research Fields Pinus massoniana Lamb. Endocrinology	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis ^[2,3].

HY-N8282

Flavoglaucin	Structural Classification Microorganisms Source classification Phenols Polyphenols	Others
Flavoglaucin is a compound that exhibits significant anti-tumor promoting activity. Flavoglaucin exhibits significant inhibition of PTP1B with an IC50 value of 13.4 micromolar. Flavoglaucin also shows good binding affinity to human opioid or cannabinoid receptors. Flavoglaucin has anti-inflammatory activity .

HY-10863

Anandamide 1 Publications Verification AEA	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-W013788R

2-Palmitoylglycerol (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-B0151

Pregnenolone 2 Publications Verification 3β-Hydroxy-5-pregnen-20-one	Structural Classification Microorganisms Neurological Disease Classification of Application Fields Anti-aging Source classification Endogenous metabolite Disease Research Fields Steroids	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy
Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication . Pregnenolone is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels .

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-W008364

Olivetol	Structural Classification Microorganisms other families Source classification Phenols Polyphenols Plants	Cytochrome P450 Cannabinoid Receptor
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

HY-B1739

Pregnenolone monosulfate 3β-Hydroxy-5-pregnen-20-one monosulfate	Structural Classification Source classification Endogenous metabolite Steroids	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy
Pregnenolone monosulfate (3β-Hydroxy-5-pregnen-20-one monosulfate) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate can protect the brain from cannabis intoxication . Pregnenolone monosulfate is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels .

HY-110189

Pregnenolone monosulfate sodium 2 Publications Verification 3β-Hydroxy-5-pregnen-20-one monosulfate sodium	Structural Classification Source classification Endogenous metabolite Steroids	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy
Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication . Pregnenolone monosulfate sodium is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels .

HY-W008364R

Olivetol (Standard)	Structural Classification Microorganisms other families Source classification Phenols Polyphenols Plants	Cytochrome P450 Cannabinoid Receptor
Olivetol (Standard) is the analytical standard of Olivetol. This product is intended for research and analytical applications. Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC50s of 15.3 μM, 7.21 μM and Kis of 2.71 μM, 2.87 μM, respectively .

HY-B0151R

Pregnenolone (Standard) 2 Publications Verification 3β-Hydroxy-5-pregnen-20-one (Standard)	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Endogenous metabolite Disease Research Fields Steroids	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy
Pregnenolone (Standard) is the analytical standard of Pregnenolone. This product is intended for research and analytical applications. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication . Pregnenolone is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels .

HY-135880A

OMDM-4	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
OMDM-4 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i 17.7 μM .

HY-121557

OMDM-1	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
OMDM-1 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 2.4 μM .

HY-135880

OMDM-3	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM .

HY-103342

OMDM-2	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
OMDM-2 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 3.0 μM .

Cat. No.	Product Name	Chemical Structure

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant[1][2].

HY-B0151S2

Pregnenolone-d4-1

Pregnenolone-d₄-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-14136S

Rimonabant-d10
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-10863S1

Anandamide-d11
Anandamide-d₁₁ is deuterium labeled Anandamide. Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55)[1][2].

HY-14137S

Rimonabant-d10 hydrochloride
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3)[1][2].

HY-10863S

Anandamide-d8

Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-113421S

Linoleoyl ethanolamide-d4

Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-B0151S1

Pregnenolone-13C2,d2

Pregnenolone- ¹³C₂,d₂ is the deuterium and ¹³C labeled Pregnenolone (HY-B0151). Pregnenolone is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[1][2][3][4].

HY-B0151S

Pregnenolone-d4

Pregnenolone-d₄ is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-110189S1

Pregnenolone monosulfate-d4 sodium

Pregnenolone monosulfate-d₄ (sodium) is the deuterium labeled Pregnenolone monosulfate. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-110189S

Pregnenolone monosulfate sodium-13C2,d2

Pregnenolone monosulfate (sodium)- ¹³C₂,d₂ is the ¹³C- and deuterium labeled Pregnenolone monosulfate sodium. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium salt acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium salt can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium salt is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

Cat. No.	Product Name		Classification

HY-155481

CB2 receptor antagonist 3		Azide
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks